NewsBenzingaBarclays behält die Einstufung „Overweight“ für Edwards Lifesciences bei und erhöht das Kursziel auf 120 US-Dollar Barclays behält die Einstufung „Overweight“ für Edwards Lifesciences bei und erhöht das Kursziel auf 120 US-Dollar Benzinga 2026.11.05 18:44 (GMT+0) Open on Benzinga Other news How Everyday Investors Are Playing the Nvidia Drama Alvotech (ALVO) Presents at UBS Global Biopharma Conference 2026 Transcript Nvidia Tops Sales Forecast After Huang's Resignation Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares Nvidia promises that revenue will keep soaring — for now CalPERS Discloses $37.1 Million Stake in Strategy
Bill Gates Has Earned $2.6 Billion in Dividends From a Landfill Stock the EPA Keeps Citing for Methane Leaks, and a Filing Shows He Just Bought 3.7M More Shares